Regeneron Pharmaceuticals Inc (REGN)

NASDAQ
Currency in USD
514.06
+5.20(+1.02%)
Real-time Data·
REGN Scorecard
Full Analysis
Management has been aggressively buying back shares
REGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
503.25519.17
52 wk Range
476.491,211.20
Key Statistics
Edit
Prev. Close
508.86
Open
508.51
Day's Range
503.25-519.17
52 wk Range
476.49-1,211.2
Volume
493.39K
Average Volume (3m)
1.32M
1-Year Change
-51.32%
Book Value / Share
274.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
REGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
727.21
Upside
+41.46%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Regeneron Pharma Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc SWOT Analysis


Eylea's Challenges
Explore Regeneron's strategy to maintain Eylea's market position amid biosimilar competition and regulatory hurdles, impacting its $4 billion franchise
Dupixent's Ascent
Discover how Dupixent's expansion into new indications could drive Regeneron's growth, with analysts projecting an 8% CAGR from 2025 to 2030
Pipeline Potential
Delve into Regeneron's promising oncology and immunology pipeline, including fianlimab for melanoma and itepekimab for COPD
Financial Outlook
Analysts maintain a positive outlook with EPS estimates around $34.50 for 2025. Price targets range from $695 to $1,215, averaging around $990
Read full SWOT analysis

Regeneron Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $8.22 missed forecast of $8.48; revenue at $3B vs expected $3.24B; stock dropped 8.19% post-announcement
  • Challenges in anti-VEGF market and patient assistance funding impacted performance; company maintains strong positions in key areas
  • Regeneron projects 86-87% gross margin for 2025; anticipates multiple U.S. regulatory approvals and continued pipeline expansion
  • CEO emphasizes company's strong scientific, commercial, and financial position despite current challenges
  • Analysts revised earnings expectations downward; stock price targets range from $547 to $1,081 per share
Last Updated: 29-04-2025, 07:18 pm
Read Full Transcript

Compare REGN to Peers and Sector

Metrics to compare
REGN
Peers
Sector
Relationship
P/E Ratio
12.1x−2.7x−0.4x
PEG Ratio
0.730.000.00
Price/Book
1.8x2.6x2.6x
Price / LTM Sales
3.9x4.2x3.0x
Upside (Analyst Target)
46.1%32.5%52.3%
Fair Value Upside
Unlock29.9%9.4%Unlock

Analyst Ratings

19 Buy
6 Hold
1 Sell
Ratings:
26 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 727.21
(+41.46% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 41.81%
Dividend Yield
0.67%
Industry Median 0.05%
Annualised payout
3.52
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
8.22 / 8.48
Revenue / Forecast
3.03B / 3.24B
EPS Revisions
Last 90 days

REGN Income Statement

FAQ

What Is the Regeneron Pharma (REGN) Stock Price Today?

The Regeneron Pharma stock price today is 514.06.

What Stock Exchange Does Regeneron Pharma Trade On?

Regeneron Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Regeneron Pharma?

The stock symbol for Regeneron Pharma is "REGN."

Does Regeneron Pharma Pay Dividends? What’s The Current Dividend Yield?

The Regeneron Pharma dividend yield is 0.69%.

What Is the Regeneron Pharma Market Cap?

As of today, Regeneron Pharma market cap is 54.53B.

What Is Regeneron Pharma's Earnings Per Share (TTM)?

The Regeneron Pharma EPS (TTM) is 41.81.

When Is the Next Regeneron Pharma Earnings Date?

Regeneron Pharma will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is REGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Regeneron Pharma Stock Split?

Regeneron Pharma has split 0 times.

How Many Employees Does Regeneron Pharma Have?

Regeneron Pharma has 15158 employees.

What is the current trading status of Regeneron Pharma (REGN)?

As of 18 Jun 2025, Regeneron Pharma (REGN) is trading at a price of 514.06, with a previous close of 508.86. The stock has fluctuated within a day range of 503.25 to 519.17, while its 52-week range spans from 476.49 to 1,211.20.

What Is Regeneron Pharma (REGN) Price Target According to Analysts?

The average 12-month price target for Regeneron Pharma is USD727.21375, with a high estimate of USD940 and a low estimate of USD504. 19 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +41.46% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.